{"nctId":"NCT02019472","briefTitle":"A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis","startDateStruct":{"date":"2014-04-04","type":"ACTUAL"},"conditions":["Arthritis, Rheumatoid"],"count":559,"armGroups":[{"label":"Group 1 (adalimumab 40 mg)","type":"EXPERIMENTAL","interventionNames":["Biological: adalimumab 40 mg"]},{"label":"Group 2 (sirukumab 100 mg)","type":"EXPERIMENTAL","interventionNames":["Biological: sirukumab 100 mg","Drug: Placebo"]},{"label":"Group 3 (sirukumab 50 mg)","type":"EXPERIMENTAL","interventionNames":["Biological: sirukumab 50 mg","Drug: Placebo"]}],"interventions":[{"name":"adalimumab 40 mg","otherNames":["HUMIRA®"]},{"name":"sirukumab 100 mg","otherNames":["CNTO 136"]},{"name":"sirukumab 50 mg","otherNames":["CNTO 136"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have a diagnosis of rheumatoid arthritis (RA) for at least 6 months before screening\n* Have moderately to severely active RA with at least 8 of 68 tender joints and 6 of 66 swollen joints, at screening and at baseline\n* Have previous or current treatment with methotrexate (MTX) and are considered intolerant to MTX, and/or are considered inappropriate for treatment with MTX, (including MTX-naïve subjects for whom it is inappropriate to administer MTX) and/or an inadequate responder to methotrexate\n* Must not have received MTX or any other non-biologic DMARD including but not limited to sulfasalazine, hydroxychloroquine, chloroquine, and bucillamine for at least 2 weeks prior to the first administration of the study agent\n* C-reactive protein \\>= 10.00 mg/L or erythrocyte sedimentation rate \\>=28 mm/hr at screening\n\nExclusion Criteria:\n\n* Has Functional Class IV as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis\n* Has ever received biologic therapy for RA, including but not limited to the following: TNF-alpha inhibitors, tocilizumab, rituximab, anakinra, abatacept\n* Has ever used tofacitinib therapy or any other JAK inhibitor\n* Has received intra-articular, intramuscular, or IV corticosteroids for RA, including adrenocorticotrophic hormone during the 4 weeks prior to first study agent administration\n* Has received leflunomide within 24 months before the first study agent administration and has not undergone a drug elimination procedure, unless the M1 metabolite is measured and is undetectable","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Disease Activity Index Score 28 (DAS28) Erythrocyte Sedimentation Rate (ESR) at Week 24","description":"The Disease Activity Index Score 28 using ESR \\[DAS28 (ESR)\\] is a derived score combining tender joints (28 joints), swollen joints (28 joints), ESR, and Patient's Global Assessment of Disease Activity. The 28 joints evaluated for swelling and tenderness were shoulder, elbow, wrist, MCP1, MCP2, MCP3, MCP4, MCP5, PIP1, PIP2, PIP3, PIP4, PIP5 joints of the upper right and upper left extremities as well as the knee joints of the lower right and lower left extremities. The DAS28-ESR is expressed on a score range of \"0-10\", with the minimum score= 0 (best) to maximum score= 10 (worst).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.89","spread":"0.851"},{"groupId":"OG001","value":"6.90","spread":"0.881"},{"groupId":"OG002","value":"6.91","spread":"0.863"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.19","spread":"1.437"},{"groupId":"OG001","value":"-2.58","spread":"1.524"},{"groupId":"OG002","value":"-2.96","spread":"1.58"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With an American College of Rheumatology (ACR) 50 Response at Week 24","description":"The ACR 50 Response is defined as greater than or equal to (\\>=) 50 percent (%) improvement in swollen joint count (66 joints) and tender joint count (68 joints) and \\>= 50% improvement in 3 of following 5 assessments: subject's assessment of pain using Visual Analog Scale (VAS) (0-10 millimeter \\[mm\\], 0 mm=no pain and 10 mm=worst possible pain), subject's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, \\[0 mm=no pain to 100 mm=worst possible pain\\]), physician's global assessment of disease activity using VAS (the scale ranges from 0 to 10, \\[0=no arthritis activity to 10=extremely active arthritis\\]), participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI) (the scale ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and serum C-Reactive Protein (CRP).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.7","spread":null},{"groupId":"OG001","value":"26.9","spread":null},{"groupId":"OG002","value":"35.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Disease Activity Index Score 28 (DAS28) Using Erythrocyte Sedimentation Rate (ESR) Remission at Week 24","description":"The Disease Activity Index Score 28 using ESR \\[DAS28 (ESR)\\] is a derived score combining tender joints (28 joints), swollen joints (28 joints), ESR, and Patient's Global Assessment of Disease Activity. The 28 joints evaluated for swelling and tenderness were shoulder, elbow, wrist, MCP1, MCP2, MCP3, MCP4, MCP5, PIP1, PIP2, PIP3, PIP4, PIP5 joints of the upper right and upper left extremities as well as the knee joints of the lower right and lower left extremities. The DAS28-ESR is expressed on a score range of \"0-10\", with the minimum score= 0 (best) to maximum score= 10 (worst). The DAS28 (ESR) remission is defined as a DAS28 (ESR) value of less than 2.6 at a visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":null},{"groupId":"OG001","value":"12.9","spread":null},{"groupId":"OG002","value":"20.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 24","description":"The ACR 20 Response is defined as \\>= 20% improvement in swollen joint count (66 joints) and tender joint count (68 joints) and \\>=20% improvement in 3 of following 5 assessments: subject's assessment of pain using VAS (0-10 mm, 0 mm=no pain and 10 mm=worst possible pain), subject's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, \\[0 mm=no pain to 100 mm=worst possible pain\\]), physician's global assessment of disease activity using VAS, subject's assessment of physical function measured by HAQ-DI, defined as a 20-question instrument assessing 8 functional areas. The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and serum CRP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.5","spread":null},{"groupId":"OG001","value":"53.8","spread":null},{"groupId":"OG002","value":"58.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":173},"commonTop":["Injection site erythema","Alanine aminotransferase increased","Rheumatoid arthritis","Aspartate aminotransferase increased","Nasopharyngitis"]}}}